{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:54:39Z","timestamp":1787849679007,"version":"build-2784847793"},"reference-count":26,"publisher":"Galenos Yayinevi","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["tjo"],"DOI":"10.4274\/tjo.galenos.2024.17971","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T07:10:59Z","timestamp":1738739459000},"source":"Crossref","is-referenced-by-count":2,"title":["Combination Therapy with Atropine 0.05% and Myopi-X\u00ae Glasses: Is it Effective in Myopia Control?"],"prefix":"10.4274","author":[{"given":"Nilay","family":"Akag\u00fcn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U\u011fur Emrah","family":"Alt\u0131parmak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2811","published-online":{"date-parts":[[2025,2,5]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1. Matsumura S, Matsumura S, Ching-Yu C, Saw SM. Global epidemiology of myopia. In: Ang M, Wong T, eds. Updates on Myopia. Singapore: Springer. 2020:3-16.","DOI":"10.1007\/978-981-13-8491-2_2"},{"key":"ref1","unstructured":"2. Flanagan J, Fricke T, Morjaria P, Yasmin S. Myopia: a growing epidemic. Community Eye Health. 2019;32:9."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.ophtha.2016.01.006","article-title":"Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050","volume":"123","author":"Holden","year":"2016","unstructured":"3. Holden BA, Fricke TR, Wilson DA, Jong M, Naidoo KS, Sankaridurg P, Wong TY, Na-duvilath TJ, Resnikoff S. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology. 2016;123:1036-1042.","journal-title":"Ophthalmology"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1167\/iovs.61.4.49","article-title":"The complications of myopia: a review and meta-analysis","volume":"61","author":"Haarman","year":"2020","unstructured":"4. Haarman AEG, Enthoven CA, Tideman JWL, Tedja MS, Verhoeven VJM, Klaver CCW. The complications of myopia: a review and meta-analysis. Invest Ophthalmol Vis Sci. 2020;61:49.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/eye.2013.254","article-title":"Genetic and environmental effects on myopia development and progression","volume":"28","author":"Goldschmidt","year":"2014","unstructured":"5. Goldschmidt E, Jacobsen N. Genetic and environmental effects on myopia development and progression. Eye (Lond). 2014;28:126-133.","journal-title":"Eye (Lond)"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6. Smith MJ, Walline JJ. Controlling myopia progression in children and adolescents. Adolesc Health Med Ther. 2015;6:133-140.","DOI":"10.2147\/AHMT.S55834"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7. Hong J, Yun CO. Emergence of ad-mediated combination therapy against cancer: what to expect? Curr Cancer Drug Targets. 2018;18:139-152.","DOI":"10.2174\/1568009617666170222123406"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1002\/cncr.32022","article-title":"Combating breast cancer using combination therapy with 3 phytochemicals: piperine, sulforaphane, and thymoquinone","volume":"125","author":"MZ","year":"2019","unstructured":"8. Aumeeruddy MZ, Mahomoodally MF. Combating breast cancer using combination therapy with 3 phytochemicals: piperine, sulforaphane, and thymoquinone. Cancer. 2019;125:1600-1611.","journal-title":"Cancer"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/dom.13108","article-title":"Initiating therapy in patients newly diagnosed with type 2 diabetes: combination therapy vs a stepwise approach","volume":"20","author":"Cersosimo","year":"2018","unstructured":"9. Cersosimo E, Johnson EL, Chovanes C, Skolnik N. Initiating therapy in patients newly diagnosed with type 2 diabetes: combination therapy vs a stepwise approach. Diabetes Obes Metab. 2018;20:497-507.","journal-title":"Diabetes Obes Metab"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41433-019-0671-0","article-title":"New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost","volume":"34","author":"Mehran","year":"2020","unstructured":"10. Mehran NA, Sinha S, Razeghinejad R. New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost. Eye (Lond). 2020;34:72-88.","journal-title":"Eye (Lond)"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3341\/kjo.2022.0125","article-title":"Peripheral defocus and myopia management: a mini-review","volume":"37","author":"Erdinest","year":"2023","unstructured":"11. Erdinest N, London N, Lavy I, Berkow D, Landau D, Morad Y, Levinger N. Peripheral defocus and myopia management: a mini-review. Korean J Ophthalmol. 2023;37:70-81.","journal-title":"Korean J Ophthalmol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ophtha.2011.07.031","article-title":"01% doses (atropine for the treatment of myopia 2)","volume":"119","author":"Chia","year":"2012","unstructured":"12. Chia A, Chua WH, Cheung YB, Wong WL, Lingham A, Fong A, Tan D. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (atropine for the treatment of myopia 2). Ophthalmology. 2012;119:347-354.","journal-title":"Ophthalmology"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3390\/jcm7090259","article-title":"The synergistic effects of orthokeratology and atropine in slowing the progression of myopia","volume":"7","author":"Wan","year":"2018","unstructured":"13. Wan L, Wei CC, Chen CS, Chang CY, Lin CJ, Chen JJ, Tien PT, Lin HJ. The synergistic effects of orthokeratology and atropine in slowing the progression of myopia. J Clin Med. 2018;7:259.","journal-title":"J Clin Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"231","DOI":"10.4103\/tjo.tjo_31_22","article-title":"Myopia control utilizing low-dose atropine as an isolated therapy or in combination with other optical measures: a retrospective cohort study","volume":"13","author":"Erdinest","year":"2022","unstructured":"14. Erdinest N, London N, Lavy I, Levinger N, Pras E, Morad Y. Myopia control utilizing low-dose atropine as an isolated therapy or in combination with other optical measures: a retrospective cohort study. Taiwan J Ophthalmol. 2022;13:231-237.","journal-title":"Taiwan J Ophthalmol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3390\/vision6040073","article-title":"combined with misight 1 day contact lenses for myopia management","volume":"6","author":"Erdinest","year":"2022","unstructured":"15. Erdinest N, London N, Lavy I, Landau D, Ben Ephraim Noyman D, Levinger N, Morad Y. Low-concentration atropine monotherapy vs. combined with misight 1 day contact lenses for myopia management. Vision (Basel). 2022;6:73.","journal-title":"Vision (Basel)"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"100923","DOI":"10.1016\/j.preteyeres.2020.100923","article-title":"Efficacy in myopia control","volume":"83","author":"Brennan","year":"2021","unstructured":"16. Brennan NA, Toubouti YM, Cheng X, Bullimore MA. Efficacy in myopia control. Prog Retin Eye Res. 2021;83:100923.","journal-title":"Prog Retin Eye Res"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"0281816","DOI":"10.1371\/journal.pone.0281816","article-title":"A comparison of myopia control in European children and adolescents with defocus incorporated multiple segments (DIMS) spectacles, atropine, and combined DIMS\/atropine","volume":"18","author":"Nucci","year":"2023","unstructured":"17. Nucci P, Lembo A, Schiavetti I, Shah R, Edgar DF, Evans BJW. A comparison of myopia control in European children and adolescents with defocus incorporated multiple segments (DIMS) spectacles, atropine, and combined DIMS\/atropine. PLoS One. 2023;18:0281816.","journal-title":"PLoS One"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"22311","DOI":"10.1038\/s41598-022-25599-z","article-title":"Synergistic effects of defocus-incorporated multiple segments and atropine in slowing the progression of myopia","volume":"12","author":"Huang","year":"2022","unstructured":"18. Huang Z, Chen XF, He T, Tang Y, Du CX. Synergistic effects of defocus-incorporated multiple segments and atropine in slowing the progression of myopia. Sci Rep. 2022;12:22311.","journal-title":"Sci Rep"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1097\/OPX.0000000000001884","article-title":"01% atropine with soft multifocal contact lenses on myopia progression in children","volume":"99","author":"Jones","year":"2022","unstructured":"19. Jones JH, Mutti DO, Jones-Jordan LA, Walline JJ. Effect of combining 0.01% atropine with soft multifocal contact lenses on myopia progression in children. Optom Vis Sci. 2022;99:434-442.","journal-title":"Optom Vis Sci"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"12750","DOI":"10.1038\/s41598-020-69710-8","article-title":"01% atropine solution for slowing axial elongation in children with myopia: a 2-year randomised trial","volume":"10","author":"Kinoshita","year":"2020","unstructured":"20. Kinoshita N, Konno Y, Hamada N, Kanda Y, Shimmura-Tomita M, Kaburaki T, Kakehashi A. Efficacy of combined orthokeratology and 0.01% atropine solution for slowing axial elongation in children with myopia: a 2-year randomised trial. Sci Rep. 2020;10:12750.","journal-title":"Sci Rep"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/opo.12722","article-title":"01% atropine with orthokeratology (AOK) study: a randomised clinical trial","volume":"40","author":"Tan","year":"2020","unstructured":"21. Tan Q, Ng AL, Choy BN, Cheng GP, Woo VC, Cho P. One-year results of 0.01% atropine with orthokeratology (AOK) study: a randomised clinical trial. Ophthalmic Physiol Opt. 2020;40:557-566.","journal-title":"Ophthalmic Physiol Opt"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"22. Chen Z, Zhou J, Xue F, Qu X, Zhou X. Two-year add-on effect of using low concentration atropine in poor responders of orthokeratology in myopic children. Br J Ophthalmol. 2022;106:1069-1072.","DOI":"10.1136\/bjophthalmol-2020-317980"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ophtha.2018.05.029","article-title":"01% atropine eye drops in myopia control","volume":"126","author":"Yam","year":"2019","unstructured":"23. Yam JC, Jiang Y, Tang SM, Law AKP, Chan JJ, Wong E, Ko ST, Young AL, Tham CC, Chen LJ, Pang CP. Low-concentration atropine for myopia progression (LAMP) Study: a randomized, double-blinded, placebo-controlled trial of 0.05%, 0.025%, and 0.01% atropine eye drops in myopia control. Ophthalmology. 2019;126:113-124.","journal-title":"Ophthalmology"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.ophtha.2019.12.011","article-title":"Two-year clinical trial of the low-concentration atropine for myopia progression (LAMP) study: phase 2 report","volume":"127","author":"Yam","year":"2020","unstructured":"24. Yam JC, Li FF, Zhang X, Tang SM, Yip BHK, Kam KW, Ko ST, Young AL, Tham CC, Chen LJ, Pang CP. Two-year clinical trial of the low-concentration atropine for myopia progression (LAMP) study: phase 2 report. Ophthalmology. 2020;127:910-919.","journal-title":"Ophthalmology"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.ophtha.2021.10.002","article-title":"Three-year clinical trial of low-concentration atropine for myopia progression (LAMP) study: continued versus washout: phase 3 report","volume":"129","author":"Yam","year":"2022","unstructured":"25. Yam JC, Zhang XJ, Zhang Y, Wang YM, Tang SM, Li FF, Kam KW, Ko ST, Yip BHK, Young AL, Tham CC, Chen LJ, Pang CP. Three-year clinical trial of low-concentration atropine for myopia progression (LAMP) study: continued versus washout: phase 3 report. Ophthalmology. 2022;129:308-321.","journal-title":"Ophthalmology"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3390\/vision8010003","article-title":"05% and MF60 contact lenses","volume":"8","author":"Erdinest","year":"2024","unstructured":"26. Erdinest N, Atar-Vardi M, London N, Landau D, Smadja D, Pras E, Lavy I, Morad Y. Treatment of rapid progression of myopia: topical atropine 0.05% and MF60 contact lenses. Vision (Basel). 2024;8:3.","journal-title":"Vision (Basel)"}],"container-title":["Turkish Journal of Ophthalmology"],"original-title":[],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T08:54:03Z","timestamp":1741596843000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oftalmoloji.org\/articles\/combination-therapy-with-atropine-005percent-and-myopi-xr-glasses-is-it-effective-in-myopia-control\/doi\/tjo.galenos.2024.17971"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,5]]},"references-count":26,"URL":"https:\/\/doi.org\/10.4274\/tjo.galenos.2024.17971","relation":{},"ISSN":["1300-0659","2147-2661"],"issn-type":[{"value":"1300-0659","type":"print"},{"value":"2147-2661","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,5]]}}}